Correction: Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway

Correction: J Exp Clin Cancer Res 37, 41 (2018)

https://doi.org/10.1186/s13046-018-0718-2

Following publication of the original article [1], the authors found errors in Fig. 5c. Figure 5C1 HT29 Cont and Figure 5 C3 SW620 Cont should show the image of HT29 and SW620 cells, respectively. The correct figure is given below:

Incorrect Fig. 5

Fig. 5.

Zeb-1 was essential for inhibition of EMT by OGN. a Cells with OGN over-expression were challenged with EGF (100 ng/mL) and transiently transfected with Zeb-1. Western blotting with the significantly altered markers was performed. b Wound healing assay and (c), cell invasion assay. The results are expressed as the mean ± SD of three independent experiments

Correct Fig. 5

Fig. 5.

Zeb-1 was essential for inhibition of EMT by OGN. a Cells with OGN over-expression were challenged with EGF (100 ng/mL) and transiently transfected with Zeb-1. Western blotting with the significantly altered markers was performed. b Wound healing assay and (c), cell invasion assay. The results are expressed as the mean ± SD of three independent experiments